Inoperable hepatocellular carcinoma: Transarterial 188Re HDD-labeled iodized oil for treatment - Prospective multicenter clinical trial

Radiology

Volumn 243, Issue 2, 2007, Pages 509-519

  Kumar, Ajay ^a   Srivastava, Deep Narayan ^a   Chau, Trinh Thi Minh ^b   Huynh, Duc Long ^b   Bal, ChandraSekhar ^a   Chandra, Prem ^a   Le, Truong Chien ^b   Nguyen, Van Hoa ^b   Thulkar, Sanjay ^a   Sharma, Sanjay ^a   Le, Huu Tam ^b   Truong, Quang Xuan ^b   Nguyen, Xuan Canh ^b   Gauri, Shankar Pant ^a   Bandopadhyaya, Guru Pad ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CHO RAY HOSPITAL   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

4 HEXADECYL 1,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANETHIOL RE 188; ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL; RHENIUM 188; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER STAGING; CLINICAL TRIAL; DEVICE; FEMALE; FEVER; HUMAN; INOPERABLE CANCER; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PAIN; PORTAL VEIN; PRIORITY JOURNAL; RADIATION DOSE; TRANSARTERIAL RADIONUCLIDE THERAPY; TUMOR CLASSIFICATION; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 34247534077     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2432051246     Document Type: Article

References (26)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225-237.
2. Llovet JM, Bustamante J, Castells A, et al. Natural history of unresected nonsurgical hepatocellular carcinoma for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67.
3. Okuda K, Takayasu K, Okada S. Treatment selection. In: Okuda K, Tabor E, eds. Liver cancer. New York, NY: Churchill-Livingstone, 1997; 435-439.
4. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000;76:4-11.
5. Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF. Simple new method for effective concentration of Re-188 solutions from alumina based W-188/Re-188 generator. J Nucl Med 2000;41:1271-1278.
6. Lee YS, Jeong JM, Kim YJ, et al. Synthesis of 188 Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237-242.
7. Ingold JA, Reed GB, Kaplan HS, Bugshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-208.
8. Margolis LW, Phillips TL. Whole lung irradiation for metastatic tumor. Radiology 1969;93:1173-1179.
9. Ho S, Lau WY, Leung TW, Johnson PJ. Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Cancer 1998;83:1894-1907.
10. Etienne G, Patrick B. Use of labeled Lipiodol in the treatment of hepatic tumors. In: Ell PJ, Gambhir S, eds. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. Hong Kong: Churchill Livingstone, 2004; 473-483.
11. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 1-131-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-1161.
12. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S194-S205.
13. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-1787.
14. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-345.
15. Risse JH, Grunwald F, Strunk H, Kleinschmidt R, Bender H, Biersack HJ. I-131-Lipiodol therapy in liver neoplasms. Hybridoma 1999;18:83-85.
16. Sundram FX, Jeong JM, Zanzonico P, et al. Transarterial Rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma-results of a multi-center phase-I study. World J Nucl Med 2002;1:5-11.
17. Sundram F, Chau TC, Onkhuudai P, Bernal P, Padhy AK. Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2004;31:250-257.
18. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
19. Bruix J, Sherman M, Llovet JM, et al. European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-430.
20. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003;38(suppl 1):S136-S149.
21. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52(suppl 3):iii1-iii8.
22. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-1261.
23. Raoul JL, Messner M, Boucher E, Bretagne JF, Campion JP, Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of I-131-labelled Lipiodol. Br J Surg 2003;90:1379-1383.
24. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial Iodine-131-labelled Lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801.
25. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54.
26. Kumar A, Bal CS, Pant GS, et al. Is scatter correction necessary for the dosimetry in transarterial Re-188-HDD-Lipiodol therapy in cases of inoperable hepatocellular carcinoma? [abstr]. Presented at the World Congress on Med Phys and Biomedical Engineering, 2003; A2069.